Background: Evidence indicates that obsessive--compulsive disorder (OCD) co-occurs with schizophrenia and bipolar disorder (BD) at a higher rate than in the general population. The inflated rate of comorbidity may result from chronic illness, antipsychotic therapy or treatment-seeking behavior. To control for these factors we evaluated the prevalence of OCD in patients with first-episode acute mania who met DSM-IV criteria for BD-I, and compared them with our previously reported group of first-episode schizophrenia patients.
Method: Fifty-six BD-I patients with a first-episode of acute mania were screened for OCD and additional comorbid disorders using the Structured Clinical Interview for DSM-IV Axis-I disorders and appropriate rating scales.
Results: Only one patient (1.8%) met DSM-IV criteria for OCD, and two (3.6%) met criteria for sub-threshold OCD. In contrast, there was a substantial aggregation of substance use disorders 32.1% (N=8), anxiety disorders, other than OCD 26.8% (N=15) and eating disorders 14.3% (N=8).
Limitations: Small sample size, cross-sectional nature of the assessments and the inclusion of only BD-I patients.
Conclusion: The rate of OCD in first-episode BD-I patients did not differ significantly from that found in the general population and was substantially lower than in previously reported first-episode schizophrenia patients (1.8% vs. 14%). We suggest that a preferential association of OCD with schizophrenia early in the course of illness represents a pathophysiological linkage between the two disorders, and putatively a specific schizo-obsessive subtype. In contrast, OCD in BD-I may stand for "true" comorbidity. Large-scale parallel comparative evaluations of comorbidity in BD-I and schizophrenia may contribute to the search for specific pathophysiological mechanisms of distinct comorbid-related subsets in either disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jad.2006.03.022 | DOI Listing |
Mol Psychiatry
January 2025
Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Child Psychiatry Hum Dev
January 2025
School of Applied Psychology, Griffith University, Gold Coast, QLD, Australia.
This pilot study evaluated the outcomes associated with a training workshop in cognitive-behavioural therapy with exposure and response prevention (ERP) for youth with obsessive-compulsive disorder (OCD) aimed at improving clinicians' capabilities and motivations. Questionnaires and role-plays were completed by 17 Australian clinicians working across community youth (i.e.
View Article and Find Full Text PDFJ Neurosurg
January 2025
1Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.
Objective: Deep brain stimulation (DBS) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (OCD). Despite being more costly than neuroablative procedures of comparable efficacy, DBS has gained popularity over the years for its reversibility and adjustability. Although the cost-effectiveness of DBS has been investigated extensively in movement disorders, few economic analyses of DBS for psychiatric disorders exist.
View Article and Find Full Text PDFEnviron Geochem Health
January 2025
College of Resource and Environmental Engineering, Hubei Key Laboratory for Efficient Utilization and Agglomeration of Metallurgic Mineral Resource, Wuhan University of Science and Technology, Wuhan, 430081, People's Republic of China.
Cadmium (Cd) contamination in aquatic systems is a widespread environmental issue. In this study, a solid waste iron tailings and biochar hybrid (Fe-TWBC) was successfully synthesized derived from co-pyrolysis of peanut shell and tailing waste (Fe-TW). Characterization analyses showed that the metal oxides from solid waste iron tailings successfully loaded onto the biochar surface, with more functional groups in Fe-TWBC.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, San Francisco, San Francisco, CA, USA.
Background: Autosomal dominant progranulin (GRN) mutations are a common genetic cause of frontotemporal lobar degeneration. Though clinical trials for GRN-related therapies are underway, there is an unmet need for biomarkers that can predict symptom onset and track disease progression. We previously showed that presymptomatic GRN carriers exhibit thalamocortical hyperconnectivity that increases with age when they are presumably closer to symptom onset.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!